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Abstract
Purpose. To report the outcome of 37 patients with metastatic osteosarcoma entered into a large randomized trial (EOI
80831/MRC B002) comparing two different regimens of chemotherapy in patients with osteosarcoma.
Methods. Patients with biopsy-proven osteosarcoma localized and metastatic, age 40 years or younger, were randomized
to receive either two-drug treatment with doxorubicin/cisplatin (DOX 25 mg m- z day- X 3 DDP 100 mg m- on
-2 day q 3 weeks 6 courses) or three-drug treatment comprising high-dose methotrexate (HDMTX 8 mg m
administered every 41/2 weeks 4 courses) given 10 days before DOX/DDP.
Results. Twenty-four patients with metastatic disease received the two-drug arm treatment and 13 received three-drug
treatment. Despite chance imbalance in numbers, there were no major differences in age, sex, primary site or performance
status. Baseline alkaline phosphatase (AP) was elevated more frequently (96 vs 42%) in the two-drug arm. Twenty-one
of 24 patients in the two-drug arm and 11/13 patients in the three-drug arm had evaluable primary tumors concurrent with
metastases. Respective clinical response rates for the two- and three-drug arms were 48% and 40% for primary tumors,
and 33% and 55% for metastases. Respective survivals at 2 and 4 years were 36% and 9% for the two-drug arm, and 69%
and 52% for the three-drug arm, and survival was better for patients with normal AP at presentation. When adjusted for
AP, survival was not significantly different between the two treatments (hazard ratio 0.52, 95% confidence interval
0.22-1.23, p 0.14). There were three long-term survivors among the metastatic patients, all of whom received the
three-drug therapy.
Discussion. It is likely that random bias in the population (small numbers, imbalance in size of groups, uneven distribution
of AP) accounts for the difference in outcome favoring the three-drug treatment in patients with metastatic disease. More
reliance can be placed on the finding that disease-free and overall survival in the adjuvant component of this study
(Bramwell et al., J Clin Oncol 1992; 10" 1579-91) were better after two-drug treatment.
Key words: osteosarcoma, chemotherapy, metastases.
Introduction
The most common type of osteosarcoma is the
so-called ’classical variety’, which occurs in the
limbs of children and young adults. Until the intro-
duction of intensive adjuvant chemotherapy, the
outlook after surgery alone was extremely poor but
with modern multi-agent chemotherapy, 5-year sur-
vival figures for non-metastatic cases range between
40 and 800/0.2
Unfortunately, between 15 and 20% of patients
with osteosarcoma will present with clinically
detectable metastases, a proportion that has
increased with sophisticated methods of detection,
such as computed tomography (CT) scanning of the
lungs. It is common to treat these patients aggres-
sively with intensive multi-agent chemotherapy, fol-
lowed by resection of metastases particularly if these
are confined to the lung, but results are poor.3’4
As determined by measurable objective response,
chemotherapy has always produced rather unim-
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pressive results in metastatic osteosarcoma. Early
data showed overall response rates for single agents
such as doxorubicin, cisplatinum, high-dose
methotrexate and ifosfamide in the range 15-25%
with even lower response rates 8-15% for agents
such as cyclophosphamide, actinomycin D, melpha-
lan, dacarbazine and mitomycin C. Similarly,
although in some studies, response rates as high as
50-80% have been reported for combination
chemotherapy, these results have usually been
obtained in very small series of patients. More fre-
quently, response rates have been in the range 25-
50%. Inclusion of patients with very tiny lung
metastases in more recent series may make evalu-
ation unreliable. Response may also be underesti-
mated, as it is not uncommon for lesions, both
primary and secondary, to calcify but not shrink on
chemotherapy. Subsequent resection sometimes
reveals these tumors to be largely necrotic and/or
fibrotic with calcification, and in some cases unre-
sected nodules may never entirely resolve.
In 1983, the European Osteosarcoma Intergroup
initiated a randomized phase II trial in which two
short intensive cytotoxic regimens were to be com-
pared for response and toxicity. Treatment in one
arm was an intensive doxorubicin/cisplatin (DOX/
DDP) regimen, and in the other arm the same drugs
were given alternately with high-dose methotrexate
(HDMTX). These were chosen because the role of
HDMTX in patients treated with other drugs
known to be highly effective in osteosarcoma was
controversial. The study recruited patients rapidly,
and the manageability and early efficacy of the regi-
mens, judged by clinical response, was such that the
study was expanded to a formal phase III trial in
which survival was the main endpoint. Results of
this protocol in non-metastatic patients who
received neo-adjuvant and adjuvant chemotherapy
have been reported previously.
6 As this protocol was
originally designed to evaluate response and toxicity,
patients presenting with initial metastases, axial or
locally recurrent tumors were also eligible for the
study, and this report describes the outcome for the
patients with metastatic disease.
Patients and methods
Study population
Patients with biopsy-proven high-grade osteosar-
coma, who were aged 40 years or younger, were
eligible for this study. To be evaluable for the cur-
rent report, patients had to have distant metastases.
The latter group included patients presenting with a
primary tumor and concurrent metastases, and
those relapsing with metastases after previous treat-
ment of a primary tumor by surgery only. At entry,
patients were required to have adequate renal func-
tion (serum creatinine < 150 #mol 1-1), hepatic
function (serum bilirubin < 20/mol 1-1) and bone
marrow reserve (white blood count >4 109/1,
platelets > 100 109/1). Informed consent was
obtained according to local institutional policies.
Patients who had received previous chemotherapy
or radiotherapy were not eligible, nor were those
with other malignancies or concomitant disease that
prevented intensive chemotherapy. Non-classic
forms of osteosarcoma such as parosteal, periosteal,
Pagetoid and post-irradiation tumors were not
included.
Trial design and therapeutic regimens
In this subgroup of patients with metastatic tumors,
the objectives were to assess clinical and radiological
response and survival. Toxicity was described in the
previous report
6 and was not quantitatively different
in this group of patients. The method of randomiza-
tion has been described previously.
6
The treatments were designed to be of equal
duration so that the planned dose intensities of
DOX plus DDP were different between the two
arms. The two-drug regimen comprised six courses
of DOX 25 mg m
-2 on days 1-3 given by intra-
venous (iv) bolus and DDP 100 mg m-
2 on day 1
given by 24-h iv infusion at 3-week intervals. The
three-drug regimen used the same DOX/DDP
chemotherapy, but only four courses were given,
-2 each preceded 10 days earlier by HDMTX 8 g m
by 4-h iv infusion with appropriate leucovorin (LV)
rescue: LV 12 mg m-
iv or 15 mg m-
for 6 h
orally began 24 h after the start ofMTX infusion for
a total of 10 doses. Serum MTX levels were mea-
sured at 24 and 48 h. If the 48-h level was below
10 -7 mol 1-1, no additional LV rescue was
required. Levels higher than this required adjust-
ment of the LV dose or duration according to a
nomogram,v Details of the hydration regimen, dose
modifications, and pretreatment and follow-up
investigations are given in the previous report.
6
Response criteria: primary
Clinical. The circumference of the limb and pri-
mary tumor length were recorded, and the treating
physician was asked to categorize the response into
complete remission, improvement, no change and
progressive disease. Accurate clinical measurement
in two perpendicular diameters was not felt to be
possible because changes in tumor masses could be
obscured by factors such as post-biopsy edema,
hematoma and muscle wasting. Components such
as pain relief and reduction in inflammatory signs
were taken into account, but the final categorization
was essentially subjective.
Radiologic. A number of factors were considered
including the length and width of the tumor on
radiographs and CT, increased ossification and, in
some cases, reduced vascularity. Although centralComparison of short intensive chemotherapy regimens 157
radiologic review was attempted, differences in tech-
nology, particularly for CT, made this a difficult
exercise and it was abandoned. Thus, radiologic
response categorization into complete remission,
improvement, no change and progressive disease
was also subjective.
Response criteria: metastases
Response of measurable metastatic disease was
assessed as follows.
Complete response. Disappearance of all symptoms
and signs of tumor determined by two observations
not less than 4 weeks apart.
Partial response. Decrease of 50% or more in the
sum of the products of measured lesions determined
by two observations not less than 4 weeks apart, and
no simultaneous increase in the size of any lesion or
the appearance of new lesions. Non-measurable
lesions had to remain stable or regress for this
category.
Stable disease. Steady state of response less than
partial remission (i.e. < 50% decrease in sum of the
products of measured lesions), or progression less
than progressive disease, of at least 6 weeks dur-
ation. There could be no appearance of new lesions
for this category.
Progressive disease. Unequivocal increase of at least
25% in the sum of the products ofmeasured lesions,
or appearance of significant new lesions.
Statistical methods
Response to treatment is presented in contingency
tables. Response to treatment being expressed as
ordered categorical variables (see earlier), compari-
sons between response rates have been performed
using the Z
2 test for trend for ordered categorical
data.8 Additionally, the Fisher exact test was per-
formed to compare overall response rates (rate of
complete plus partial responses). Exact methods
were used to compute confidence intervals (CI) of
overall response rates and of their difference. The
probability of survival was calculated using the
Kaplan-Meier estimate,
9 and comparison between
therapeutic groups used the log-rank test. The test
was subsequently adjusted1 for the initial level of
alkaline phosphatase (AP).
Results
Between January 1983 and December 1986, 307
patients were registered in the entire study. As it
proved impossible to obtain sufficient data to deter-
mine eligibility and survival for patients who were
entered by one cooperative group and two addi-
tional centres, the entire set (30 patients) for these
institutions was removed. There were five more
patients than documented in a previous report of
neo-adjuvant/adjuvant cases,
6 as the excluded group
now contains patients with metastatic disease. Two
hundred and twenty-eight adjuvant and neo-
adjuvant cases have been previously reported.
6
Seven patients with axial and three with locally
recurrent tumors, not associated with metastases,
are not considered further in this report.
Of 39 patients with metastatic disease, two
patients who received the three-drug regimen were
considered to be ineligible. One patient with a pri-
mary tumor in the upper humerus was originally
thought, on angiography, to have involved axillary
lymph nodes, but this could not be confirmed at
subsequent review. The second patient had received
prior chemotherapy. Thus, 37 patients with
metastatic disease at presentation are the subject of
this report.
The clinical characteristics of the metastatic cases
are shown in Table 1. Twenty-four cases were ran-
domized to receive the two-drug regimen and 13 to
receive the three-drug regimen. Allowing for small
numbers and a chance excess of cases in the two-
drug arm, there were no major differences in charac-
teristics such as age, sex, primary site and
performance status according to treatment arm. The
median age was 18 years. Elevated levels of serum
AP at presentation were observed more frequently
(96% vs 42%) in the two-drug arm. In 21/24
patients in the two-drug arm and 11/13 patients in
the three-drug arm, metastases were present concur-
rent with the primary tumor.
Eleven patients (46%) completed the full course
of six treatment cycles on the two-drug arm. Pro-
gression of disease occurred in nine patients after
one (one patient), two (one patient), three (four
patients), four (two patients) and five (one patient)
cycles. Two patients refused treatment after three
and five cycles, and two patients stopped after five
cycles because of liver function abnormalities and
impaired renal function, respectively. In contrast, on
the three-drug regimen, only two patients failed to
complete the full course of four cycles of chemo-
therapy, terminating after one and three cycles, in
both cases due to disease progression. Eight patients
received the four planned cycles and three patients
with responding disease received one to three addi-
tional cycles.
In the two-drug arm, 10/21 patients had resection
of the primary tumor. In eight cases this was per-
formed after three cycles of chemotherapy, as
recommended in the protocol. In one patient, who
did not receive the last two cycles because of pro-
gressive lung metastases, an above-knee amputation
was performed 6 months later. A second patient,
who achieved partial remission of both an upper
humeral primary and metastases, underwent con-
servative surgery with insertion of a prosthesis after
six cycles of chemotherapy. Five patients who had158 V. H. C. Bramwell et al.
Table 1. Clinical characteristics, patients
Parameter Two-drug Three-drug Total
Age, years
<12 2 0 2
12-16 5 5 10
> 16 17 8 25
Sex
Male 15 7 22
Female 9 6 15
Kamofsky PS
80-100 17 8 25
60-70 6 5 11
Unknown 0
Alkaline phosphatase
Normal 7 8
Elevated 23 5 28
Unknown 0
Primary sites
Limbs 23 12 35
Axial 2
Metastatic sites
Lung 16 11 27
Bone 3 0 3
Liver 0
Skin 0
Lung and bone 0
Lung, bone and nodes 0
Unknown 2 3
Total 24 13 37
clinical or radiological response of the primary, one
with no change and five with progressive disease were
considered inoperable. In the three-drug arm, 10/11
patients had resection of the primary tumor. In six
cases, this was performed after two cycles of chemo-
therapy, as recommended in the protocol. One
patient had surgery 2 weeks after the start of the first
cycle because of a pathological fracture, and another
had early surgery after the HDMTX component of
the second cycle because of progressive disease.
Surgery was delayed until after theHDMTX compo-
nent ofcycle 3, for administrative reasons in one case,
and in the fourth case surgery was delayed until after
four cycles in a patient showing a good clinical and
radiological response to chemotherapy.
Table 2 illustrates clinical and radiological
responses documented for primary tumors and
metastases. For the two-drug arm, by clinical evalu-
ation there were two complete responses (CRs) and
eight partial responses (PRs) (overall response rate
48%, exact 95% CI 25-71%) in 21 primary tumors
(19 assessable) although only three (14%) of these
responses were confirmed by radiology (plain radio-
graphs or CT scan). For the three-drug arm, by
clinical evaluation there was one CR and three PRs
(overall response rate 40%, exact 95% CI 12-74%)
in 10 primary tumors (seven assessable), although
only one (10%) of these was confirmed by
radiology.
As far as metastases were concerned, in the two-
drug arm, there was one CR and six PRs in 21
patients with radiologically evaluable metastases
(overall response rate 33%, exact 95% CI 14-57%).
In contrast, in the three-drug arm, there were three
CRs and three PRs in 11 patients with evaluable
metastases (overall response rate 55%, exact 95% CI
23-84%). The estimated difference in overall
response rate is 21% (in favor of the three-drug arm)
with a 95% exact CI ranging from 16% + 61%;
the observed difference in overall response rate
between therapeutic arms is not significant (Fisher
exact two-sided test: p- 0.28). When the response
distribution was compared by the g
2 test for trend for
ordered categorical variables, no significant differ-
ence was found between therapeutic arms (p 0.13)
The median follow-up is 8.6 years and 90% of
patients have been followed for more than 6 years.
Two-year survival figures are 36% and 69% for two-
and three-drug arms, respectively, falling to 9% and
52% at 4 years (unadjusted hazard ratio 0.38, 95%
CI 0.18-0.77; unadjusted log-rank test p= 0.008).
However, when the comparison between the treat-
ment arms was adjusted for the imbalance of AP
levels (Fig. 1), excluding one patient for whom AP
was unknown, the difference in survival was no
longer significant (hazard ratio 0.52, 95% CI 0.22-
1.23; p 0.14). An ’intent to treat’ analysis, includ-
ing eligible and the two ineligible patients, provides
similar hazard ratios and confidence limits.
Three patients are surviving long-term at 7.5, 10.9
and 11.6 years, all of whom were treated on the
three-drug arm. In addition, these three patients
presented with normal AP and small metastases in
the lung as the only site of distant spread. Two of the
three had their lung metastases resected. One patient
treated on the three-drug arm, who had progressive
lung and bone metastases, was lost to follow-up at
1.5 years. A second patient on the two-drug arm,
with progression in lung and brain, was lost to
follow-up at 1.3 years. All remaining patients have
died.
Discussion
The most striking initial observation in this study was
the significantly better survival for patient, with
metastatic disease treated on the three-drug arm, and
the fact that all three long-term survivors received
this regimen. In addition, a higher proportion of
patients in the three-drug arm (10/11 vs 10/21)
initially considered to be operable went on to have
definitive resection ofthe primary tumor. This appar-
ent superiority of the three-drug arm is in marked
contrast with the results ofthe adjuvant/neo-adjuvant
component of the study
6 in which continuous dis-
ease-free survival was significantly better (p 0.02)
for patients treated on the two-drug arm, with a
similar trend for overall survival (p- 0.10).Comparison of short intensive chemotherapy regimens 159
Table 2. Clinical and radiological responses: primary tumors and metastases
Site
Response Clinical
Treatment Radio* CR PR NC PD N/A A
Primary tumor Two drug
Three-drug
Metastases Two-drug
Three-drug
CR
PR
NC
PD
N/A
A
Total
CR
PR
NC
PD
N/A
A
Total
2
3 1
2
2
0
5
7
5
3 3
8 5 4 2 3 24
0
1 2
2 2
2 2
2 2 5
2 2
3 4 0 3 2 13
6 5 9 3 0 24
3 3 2 3 2 0 13
*Plain radiographs or CT scan; CR complete response; PR- partial response; NC no
change; PD progressive disease; N/A not assessable; A no tumor present.
100
90
80
70
60
50
40
30
20
10
0 N
0 2 4 6 8
Number of patients at risk
(years)
10 12
23 24 8 2 0 0 02 drugs
9 13 8 6 3 2 2 3 drugs
Fig. 1. Overall survival in patients with metastatic osteosar-
coma, adjusted according to level ofAP at presentation.
Two important explanations for the discrepancy
should be considered:
(1) The difference in effect of the two types of
chemotherapy on patients with primary vs
metastatic disease has occurred by the play of
chance in small populations.
(2) The two types of chemotherapy produced a
different biological effect in patients with pri-
mary vs metastatic disease.
However, there is a small number of patients, a
disparity in the distribution of numbers between the
two regimens and an imbalance of known (particu-
larly baseline AP levels) prognostic factors in the
metastatic component of the study. It is notable that
only one patient in the two-drug arm had a normal
AP, whereas seven (58%) had normal levels in the
three-drug arm, including all three long-term sur-
vivors. Indeed, when adjusted for the imbalance of
AP levels between the two therapeutic arms, the
difference in survival is no longer apparent.
There is little information in the literature to
support the alternative explanation. Many investiga-
torsTM believe strongly that HDMTX is an essen-
tial component of multi-agent chemotherapy for
non-metastatic osteosarcoma and that its efficacy
depends on the method of administration. Dose,
frequency and concomitant hydration/leucovorin
rescue may be crucial, and Delepine et al.7 advocate
adaptation of dose based on individual pharmacoki-
netics. However, patients in both the adjuvant and
metastatic components of this study received similar
treatment on the three-drug arm.
Different degrees of histological response between
26 primary tumors and concurrent lung metastases
resected after a more intensive regimen containing
the same three drugs as in the current study have
been reported by Bacci et al. 18 although discordant
responses were observed in only 15% of cases and
both primary tumors and metastases showed a simi-
lar rate (25%) of good responses. However, there
does not seem to be any comparative data describ-
ing the effects of different chemotherapy regimens
on primary tumors vs metastases.
Our results confirm those of others that the prog-
nosis of patients with metastases at presentation is
extremely poor. Only 3/37 (8%) were long-term
survivors in this series. Pacquement et al.
3 reported
long-term outcome for 73 patients receiving a var-
iety of chemotherapy regimens given by members of160 V.H.C. Bramwell et al.
the French Society of Pediatric Oncology, between
1980 and 1990. At a median 7 years follow-up, 13
patients (18%) were alive and disease free. Simi-
larly, only 7/62 (11%) such patients treated at
Memorial Sloan Kettering Cancer Center 1975-
1984 with five chemotherapy regimens (T4, T5, T7,
T10, T12) were alive at a minimum of 8 years
follow-up.
4
In conclusion, it is likely that random bias in the
population (small numbers, imbalance in size of the
groups, uneven distribution of AP) accounts for the
apparent difference in outcome favouring the three-
drug treatment. More reliance can be placed on the
finding that disease-free and overall survival in the
adjuvant study
6 were better after two-drug treat-
ment.
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